Viking Therapeutics

205 articles about Viking Therapeutics

• Viking Therapeutics to Report Financial Results for First Quarter 2022 on April 27, 2022

  4/20/2022

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the first quarter 2022, after the market close on Wednesday, April 27, 2022.

• Viking Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

  4/6/2022

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the 21st Annual Needham Virtual Healthcare Conference.

• Viking Therapeutics to Present at Upcoming Investor Conferences in March 2022

  3/8/2022

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that the company will present at two upcoming investor conferences.

• Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update

  2/9/2022

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced its financial results for the fourth quarter and year ended December 31, 2021, and provided an update on its clinical pipeline and other corporate developments.

• Viking Therapeutics to Present at SVB Leerink 11th Annual Global Healthcare Conference

  2/7/2022

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), today announced that its chief executive officer, Brian Lian, Ph.D., will participate in a fireside chat as part of the SVB Leerink 11th Annual Global Healthcare Conference.

• Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2021 on February 9, 2022

  2/2/2022

  Viking Therapeutics, Inc. announced today that the company will release financial results for the fourth quarter and year-end 2021, after the market close on Wednesday, February 9, 2022.

• 

  Viking X-ALD Study Paused Over Conflicting Phase Interpretations

  1/27/2022

  The FDA is calling the study a phase II trial and says the company must run a rodent genotoxicity study before it can continue.

• Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK2735, Company's Lead Dual GLP-1/GIP Receptor Agonist

  1/10/2022

  Viking Therapeutics, Inc. announced the initiation of a Phase 1 single ascending dose and multiple ascending dose clinical trial of VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors.

• Viking Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference

  1/3/2022

  Viking Therapeutics, Inc. today announced that its chief executive officer, Brian Lian , Ph.D., will deliver a corporate presentation as part of the H.C. Wainwright BioConnect 2022 Conference.

• Viking Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference

  11/9/2021

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the Stifel 2021 Virtual Healthcare Conference.

• Viking Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

  11/3/2021

  Viking Therapeutics, Inc. today announced its financial results for the third quarter and nine months ended September 30, 2021, and provided an update on its clinical pipeline and other corporate developments.

• Viking Therapeutics Presents Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek® 2021

  11/1/2021

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced the presentation of preclinical data from a series of internally developed dual agonists of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors at ObesityWeek® 2021.

• Viking Therapeutics to Report Financial Results for Third Quarter 2021 on November 3, 2021

  10/27/2021

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the third quarter 2021, after the market close on Wednesday, November 3, 2021.

• Viking Therapeutics to Present Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek 2021

  10/25/2021

  Viking Therapeutics, Inc. today announced that preclinical data from a series of novel dual agonists of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors will be presented at ObesityWeek 2021, the annual meeting of The Obesity Society.

• Viking Therapeutics to Present at H.C. Wainwright's 5th Annual NASH Investor Conference

  10/5/2021

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of H.C. Wainwright's 5th Annual NASH Investor Conference. 

• Viking Therapeutics to Participate in Upcoming Investor Conferences in September 2021

  9/2/2021

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that the company will participate in four upcoming investor conferences.

• Viking Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

  7/28/2021

  Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2021, and provided an update on its clinical pipeline and other corporate developments.

• Viking Therapeutics Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients with X-ALD

  6/24/2021

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced the initiation of a Phase 1b clinical trial of VK0214, a novel small molecule agonist of the thyroid hormone receptor beta, in patients with X-linked adrenoleukodystrophy.

• Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214

  6/17/2021

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced results from the company's Phase 1 single ascending dose and multiple ascending dose clinical trial of VK0214, a novel, orally available small molecule thyroid receptor beta agonist in development for the potential treatment for X-linked adrenoleukodystrophy.

• Viking Therapeutics to Participate in Upcoming Investor Conferences - June 10, 2021

  6/10/2021

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that the company will participate in two upcoming investor conferences.